Member Info for BuenaVista

@Bella, that's a fallacous argument and, to what should be no one's surprise, you have fooled several board members.

"Avacta right now has no way of funding the Research/Trials for own products to market..." is just not relevant because when a major signs a deal the major takes on the cost of clinical development in return for a share of the sales, or some other arrangement. I'm not saying it would be that way for Avacta and I'm not saying there won't be a royalty agreement with Healthcare Royalties, just that you seem blinkered by your intuition. The fact is, no one knows what deal(s) is/are being lined up. Personally, I would prefer the kudos of a major taking a stake but I don't make predictions that are beyond hopes - now there's a challenge for one of the Sherlocks to go through my posting history.

Hello Myles

@Safebreaker, I wasn't having a dig at you. Sorry if you thought I was; I was making general points as to why democracy cannot be perfect.

Great news for Avacta's pre|CISION platform!

@Safebreaker, (nearly) all governments are corrupt to some extent, including democracies, but autocracies are a whole different level of corruption (and associated incompetence). Best to get money, particularly foreign money, out of the media and electoral system but that's not going to happen unless social media is stamped down on, but a democracy would never dare impose such a restriction on liberty. The bottom line.. we're all lost to mankind's greed for power, money and influence.

A good book which explains clearly how politics works, not just in dictatorships or democracies but also in boardrooms (see CC's manoeuvring since she became CEO for example) and international organisations such as FIFA and the IOC is 'The Dictator's Handbook: Why bad behavior is almost always good politics'.

@Bella, maybe, maybe not, I'm not fussed. But you were saying "the use of high speed computers, algorithums and AI mean that trades can be transacted in nano seconds...if 2 large trades are put through and then one is immediately cancelled" but why would it be 'a mistake' if it was being controlled by an algorithm working on, actually, fractions of a nanosecond and not by manual entry?

@Harrogate, AstraZeneca already has a US listing but the main listing is in London and there are no current plans (that is, no announcement) to just list in the US. Maybe you were thinking of the investment announced last week? - Significant investments in US manufacturing and research facilities, totalling $50 billion by 2030.

@SYN00GOLD, which AstraZeneca site was that?

What is the mistake being corrected if it's all being done in nano seconds?

There is a discrepancy between when the Avacta RNS said the presentation would take place (Friday, 17 Oct) and what it says on the ESMO website (Sunday, 19 Oct):

Title: A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

Session Title: Developmental Therapeutics

Session Date and Time: 17 October, 19:40 - 20:00

Location: Berlin Auditorium - Hub 27

Abstract Presentation Number: 964P

Speaker: William D. Tap

https://www.lse.co.uk/rns/AVCT/avacta-to-present-at-esmo-congress-u6jnp2dn669m5io.html

- - -

Sunday, 19 October 2025, 12:00-12:45 CEST

Developmental therapeutics

964P - A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

Presentation Number 964P

Speakers William D. Tap (New York, United States of America, NY)

https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal/poster_session_sunday

- - - - - - -

I can only assume that Bill Tap is giving an extra presentation during the dead period at the end of the first day of the conference. Expecting a lot of interest? Hopefully!

The ESMO conference takes place just before the next Heights repayment on Tuesday, 21st October. That makes for very tight timing to get the latest Phase 1a data out in time to entice HNWIs and improve the share price. The news shouldn't be publicly available until trading starts on Monday, 20th and that creates an issue for raising cash from a private placing. Will Avacta pay in cash and then do a private placing, or do the private placing before the latest Phase 1a data is publicly available (with consequent questions about insider information), or will Avacta do a bigger placing after ESMO (and also after possible data about AVA6103 and AVA7100 presented at AACR-NCI-EORTC immediately after ESMO)?

In the meantime we will have the interims at the end of September, with possible Phase 1b news then, or earlier, and there is always the possibility of news of funding from licensing and/or partnering and/or other dropping at any time which would obviate the need for a placing of any kind.

Https://www.michaelnugent.com/wp-content/uploads/2014/11/Wondermark-Sea-Lion.png

Heed the siren wailing of the wyndrum at your peril.

It's just a trader trying desperately to talk the share price down by spouting lies and misinformation so that it can buy back in.

Do not engage.

Possibly through AffyXell and AFX-002 for MS?

Again wynbag takes everyone for simpletons and quotes share price when the true measure of a company's value is the marker capitalisation.

{share price} x {number of shares} = {market capitalisation}

The trial started 4 years ago. wyndrum reported for spreading misinformation. I suggest everyone else does the same.

And wyndrum, just go away you obnoxious piece of detritus.

Pre|CISION is highly sophisticated in its mode of action. It's the Holy Grail.

This tech is not new, although the technique may well have been developed, with associated patents, over the years.

Here is a review from 2018: Ultrasound-guided Microbubble in the Treatment of Cancer: A Mini Narrative Review ( https://pmc.ncbi.nlm.nih.gov/articles/PMC6217872/ )

Included in the references is this from 2009: Design and Evaluation of Doxorubicin-containing Microbubbles for Ultrasound-triggered Doxorubicin Delivery: Cytotoxicity and Mechanisms Involved ( https://pmc.ncbi.nlm.nih.gov/articles/PMC2839231/ )

The tech only seems useful for tumours with known locations, which rather suggests primary cancer, not metastatic cancer.

Ultrasound does seem to increase cell permeability and hence uptake of free doxorubicin. So a possible adjunct to AVA6000 therapy?

I hear Avacta's cleaning company is also doing really well .

Well I like Affimers. But I also like Aptamers. But which is best? There's only one way to find out... Antagonise!!!

Massive volume over at Aptamer. £66k traded already so far today.